This pilot study found that while ticagrelor monotherapy after primary PCI for STEMI did not show a significant difference in ischemic events compared to dual antiplatelet therapy, it demonstrated a trend towards lower rates of overall clinical bleeding events and a significant reduction in non-access site bleeding events.
P2Y12 inhibitor monotherapy after complex PCI; ticagrelor monotherapy in STEMI; endotype-based treatment in ANOCA; vasomotor dysfunction after PCI; collapse of a new-generation magnesium scaffold; and more
AnchorMan vs Watchman for LAA closure; TAVI with intra- or supra-annular self-expanding valves; prosthesis-patient mismatch after TAVI; VARC-HBR validation; percutaneous mechanical aspiration in left-sided infective endocarditis; concomitant transfemoral TAVI and TMVR; and more